Login to Your Account

NewCo News

Bellicum Pharma Goes To War Using its Cell Therapy

By Marie Powers
Staff Writer

Tuesday, November 15, 2011
Bellicum Pharmaceuticals Inc., whose name loosely translates from Latin as "call to war," is developing technology that seeks out and eliminates the donor T cells that cause graft-vs.-host disease (GVHD), an often-fatal complication of allogeneic hematopoietic stem cell transplantation (HSCT) in patients with acute leukemia.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription